GlaxoSmithKline reported 2.68B in Selling and Administration Expenses for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbvie ABBV:US $ 3.06B 110M
Alcon AG ALC:SW 734M 72M
Amgen AMGN:US $ 1.23B 197M
AstraZeneca AZN:LN 3.06B 1.03B
Bayer BAYN:GR 3.94B 346M
Biogen BIIB:US $ 634.9M 153M
Bristol Myers Squibb BMY:US $ 1.83B 523M
Eli Lilly And LLY:US $ 1.56B 34.1M
Fresenius FRE:GR 1.48B 10M
Fresenius Medical Care FME:GR 871.24M 48.03M
Galapagos GLPG:NA 62.34M 2.75M
Genmab GEN:DC 452M 60M
Gilead Sciences GILD:US $ 1.08B 567M
GlaxoSmithKline GSK:LN 2.68B 227M
Glaxosmithkline GSK:US 2.68B 227M
GRIFOLS GRF:SM 249.86M 7.28M
H. Lundbeck A/S LUN:DC 1.64B 377M
Hikma Pharmaceutical HIK:LN 256M 24M
Merck MRK:GR 1.37B 172M
Merk MRK:US $ 2.3B 518M
Novartis NOVN:VX 3.5B 486M
Orion ORNBV:FH 61.3M 11.7M
Philips PHIA:NA 1.22B 80M
Recordati REC:IM 121.73M 12.09M
Regeneron Pharmaceuticals REGN:US $ 450M 109.6M